Treatment with LODER-encapsulated anti-KRASG12D siRNA (siG12D LODER) inhibits cancer cell proliferation and epithelial-mesenchymal transition with significant decrease in KRAS levels and inhibits orthotopic pancreatic tumor growth and prolonged mouse survival in vivo. This evidence concerns the gene KRAS and pancreatic neoplasm.